Medipharm Labs Corp T.LABS

Alternate Symbol(s): MEDIF

Healthcare Cannabis

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.

TSX:LABS - Post by User

Medipharm Labs Corp > Negative gross margin

<< Previous

Bullboard Posts

Next >>

Comment by lscfaon Nov 15, 2021 4:25pm

137 Views

Post# 34129018

RE:Negative gross margin

solution is scale the biz. LABS mgmt, get on with it.

		MediPharm	Valens
Q1	Revenue	5,495	21,774
	adj. ebitda	(6,159)	(2,241)
	adj gross profit	(680)	4,768
	gross margin	(12.4%)	21.9%

Q2	Revenue	5,072	20,469
	adj. ebitda	(3,675)	(4,960)
	adj gross profit	(1,419)	4,136
	gross margin	(28.0%)	20.2%

Q3	Revenue	5,401	24,569
	adj. ebitda	(5,622)	(6,183)
	adj gross profit	(1,354)	5,629
	gross margin	(25.1%)	22.9%